

**STATEMENT OF UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED
31st DECEMBER ' 2022.**

| | | | | | | | Rs.in Lacs |
|----------|---|-----------------------|------------------|------------------|--------------------|--------------------|--------------------|
| PART - I | | STANDALONE | | | | | |
| Sl. No. | PARTICULARS | For the Quarter Ended | | | For 9 Months Ended | | For the Year Ended |
| | | 31/12/2022 | 30/09/2022 | 31/12/2021 | 31/12/2022 | 31/12/2021 | 31/03/2022 |
| | | UN-AUDITED | UN-AUDITED | UN-AUDITED | UN-AUDITED | UN-AUDITED | AUDITED |
| | | (1) | (2) | (3) | (4) | (5) | (6) |
| 1 | Income | | | | | | |
| | Revenue from operations | 34,848.90 | 27,840.18 | 39,158.53 | 96,568.99 | 95,637.49 | 1,32,022.21 |
| | Other Income | 1,251.05 | 1,038.94 | 927.43 | 3,379.74 | 5,339.22 | 18,778.80 |
| | Total income | 36,099.95 | 28,879.12 | 40,085.96 | 99,948.73 | 1,00,976.71 | 1,50,801.01 |
| 2 | Expenses | | | | | | |
| | a) Cost of materials consumed | 13,516.42 | 8,433.67 | 11,847.97 | 33,179.49 | 32,917.83 | 45,945.64 |
| | b) Purchases of stock-in-trade | - | - | - | - | - | - |
| | c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | (2,650.99) | 33.02 | 96.07 | (4,182.10) | (4,041.18) | (6,035.21) |
| | d) Employee benefits expense | 2,726.37 | 2,588.69 | 2,500.87 | 7,794.32 | 6,936.19 | 10,048.39 |
| | e) R & D expense | 226.99 | 207.46 | 218.85 | 657.68 | 821.03 | 1,035.45 |
| | f) Finance costs | 137.94 | 29.03 | 74.17 | 310.22 | 404.23 | 623.10 |
| | g) Depreciation and amortisation expenses | 1,091.38 | 1,075.57 | 1,050.60 | 3,221.73 | 2,867.63 | 3,909.71 |
| | h) Manufacturing Expenses | 4,599.26 | 4,449.52 | 4,625.81 | 13,187.47 | 12,884.52 | 17,318.86 |
| | i) Other Expenses | 1,724.14 | 1,463.55 | 1,266.16 | 5,087.18 | 3,877.14 | 5,710.25 |
| | Total expenses | 21,371.51 | 18,280.51 | 21,680.50 | 59,255.99 | 56,667.39 | 78,556.19 |
| 3 | Profit before exceptional items & Tax (1-2) | 14,728.44 | 10,598.61 | 18,405.46 | 40,692.74 | 44,309.32 | 72,244.82 |
| 4 | Exceptional Items | - | - | - | - | - | - |
| 5 | Profit before Tax (3-4) | 14,728.44 | 10,598.61 | 18,405.46 | 40,692.74 | 44,309.32 | 72,244.82 |
| 6 | Tax Expenses | | | | | | |
| | a) Current tax | 3,715.23 | 2,562.47 | 4,620.66 | 10,165.80 | 10,615.02 | 15,763.03 |
| | b) Deferred tax | 66.59 | 143.86 | 85.27 | 282.87 | 330.89 | 671.91 |
| 7 | Net Profit/ (Loss) for the period/year(5-6) | 10,946.62 | 7,892.28 | 13,699.53 | 30,244.07 | 33,363.41 | 55,809.88 |
| 8 | Other Comprehensive Income | | | | | | |
| 8.a | (i) Items that will not be reclassified to profit or loss | (25.48) | (25.49) | (27.95) | (76.45) | (83.89) | (101.95) |
| | (ii) Income tax relating to items that will not be reclassified to profit or loss | 6.41 | 6.42 | 7.03 | 19.24 | 21.11 | 25.66 |
| 8.b | (i) Items that will be reclassified to profit or loss | - | - | - | - | - | - |
| | (ii) Income tax relating to items that will be reclassified to profit or loss | - | - | - | - | - | - |
| | Total other Comprehensive Income | (19.07) | (19.07) | (20.92) | (57.21) | (62.78) | (76.29) |
| 9 | Total Comprehensive Income for the period (7+8) | 10,927.55 | 7,873.21 | 13,678.61 | 30,186.86 | 33,300.63 | 55,733.59 |
| 10 | Paid-up equity share capital | 2,545.65 | 2,545.65 | 2,545.65 | 2,545.65 | 2,545.65 | 2,545.65 |
| | Face Value of the Share | Re.1.00 | Re.1.00 | Re.1.00 | Re.1.00 | Re.1.00 | Re.1.00 |
| 11 | Other Equity | - | - | - | - | - | 1,49,523.67 |
| 12 | Earning Per Share (EPS)-Face value of Rs.1/- each | | | | | | |
| | a) Basic | 4.30 | 3.10 | 5.38 | 11.88 | 13.11 | 21.92 |
| | b) Diluted | 4.30 | 3.10 | 5.38 | 11.88 | 13.11 | 21.92 |
| | | (not annualised) | (not annualised) | (not annualised) | (not annualised) | (not annualised) | (annualised) |

| PART - II | | CONSOLIDATED | | | | | |
|-----------|---|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Sl. No. | PARTICULARS | For the Quarter Ended | | | For 9 Months Ended | | For the Year Ended |
| | | 31/12/2022 | 30/09/2022 | 31/12/2021 | 31/12/2022 | 31/12/2021 | 31/03/2022 |
| | | UN-AUDITED | UN-AUDITED | UN-AUDITED | UN-AUDITED | UN-AUDITED | AUDITED |
| | (1) | (2) | (3) | (4) | (5) | (4) | |
| 1 | Income | | | | | | |
| | Revenue from operations | 35,377.17 | 27,840.18 | 39,158.53 | 97,097.26 | 95,637.49 | 1,32,022.21 |
| | Other Income | 1,301.12 | 1,092.00 | 6,468.51 | 3,496.43 | 7,550.91 | 9,238.03 |
| | Total income | 36,678.29 | 28,932.18 | 45,627.04 | 1,00,593.69 | 1,03,188.40 | 1,41,260.24 |
| 2 | Expenses | | | | | | |
| | a) Cost of materials consumed | 13,603.62 | 8,575.01 | 11,847.97 | 33,452.18 | 32,917.83 | 45,945.64 |
| | b) Purchases of stock-in-trade | | | - | | | |
| | c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | (2,639.91) | 21.93 | 96.07 | (4,182.11) | (4,041.18) | (6,035.21) |
| | d) Employee benefits expense | 2,967.54 | 2,864.78 | 2,500.87 | 8,490.88 | 6,936.19 | 10,048.39 |
| | e) R & D expense | 226.98 | 207.46 | 218.85 | 657.67 | 821.03 | 1,035.45 |
| | f) Finance costs | 138.27 | 29.34 | 74.17 | 312.77 | 404.23 | 623.10 |
| | g) Depreciation and amortisation expense | 1,223.90 | 1,203.05 | 1,050.60 | 3,577.41 | 2,867.63 | 3,909.71 |
| | h) Manufacturing Expenses | 4,736.40 | 4,614.82 | 4,625.81 | 13,582.17 | 12,884.52 | 17,318.86 |
| | i) Other Expenses | 1,813.06 | 1,568.24 | 1,266.91 | 5,350.83 | 3,878.61 | 5,766.55 |
| | Total expenses | 22,069.86 | 19,084.63 | 21,681.25 | 61,241.80 | 56,668.86 | 78,612.49 |
| 3 | Profit before exceptional items , Tax & share in profit/(Loss) of Associates (1-2) | 14,608.43 | 9,847.55 | 23,945.79 | 39,351.89 | 46,519.54 | 62,647.75 |
| 4 | Add : Share of profit/(Loss) of Associates. | - | - | - | - | 4,111.23 | 4,111.23 |
| 5 | Profit before exceptional items, Tax (3+4) | 14,608.43 | 9,847.55 | 23,945.79 | 39,351.89 | 50,630.77 | 66,758.98 |
| 6 | Exceptional Items | - | - | - | - | - | - |
| 7 | Profit before Tax (5-6) | 14,608.43 | 9,847.55 | 23,945.79 | 39,351.89 | 50,630.77 | 66,758.98 |
| 8 | Tax Expenses | | | | | | |
| | a) Current tax | 3,769.77 | 2,498.06 | 6,843.36 | 10,337.11 | 13,075.93 | 19,040.47 |
| | b) Deferred tax | 66.60 | 143.86 | 1,095.53 | 282.88 | 1,341.15 | 2,338.02 |
| 9 | Net Profit/ (Loss) for the period/year(7-8) | 10,772.06 | 7,205.63 | 16,006.90 | 28,731.90 | 36,213.69 | 45,380.49 |
| 10 | Other Comprehensive Income | | | | | | |
| 10.a | (i) Items that will not be reclassified to profit or loss | (25.60) | (25.60) | (27.95) | (76.77) | (83.89) | (101.95) |
| | (ii) Income tax relating to items that will not be reclassified to profit or loss | 6.41 | 6.42 | 7.03 | 19.24 | 21.11 | 25.66 |
| 10.b | (i) Items that will be reclassified to profit or loss | - | - | - | - | - | - |
| | (ii) Income tax relating to items that will be reclassified to profit or loss | - | - | - | - | - | - |
| | Total other Comprehensive Income | (19.19) | (19.18) | (20.92) | (57.53) | (62.78) | (76.29) |
| 11 | Total Comprehensive Income for the period (9 + 10) | 10,752.87 | 7,186.45 | 15,985.98 | 28,674.37 | 36,150.91 | 45,304.20 |
| 12 | Paid-up equity share capital Face Value of the Share | 2,545.65 Re.1.00 | 2,545.65 Re.1.00 | 2,545.65 Re.1.00 | 2,545.65 Re.1.00 | 2,545.65 Re.1.00 | 2,545.65 Re.1.00 |
| 13 | Other Equity | - | - | - | - | - | 1,50,172.39 |
| 14 | Earning Per Share (EPS)- (Face value of Rs.1/- each) | | | | | | |
| | a) Basic - | 4.23 | 2.83 | 6.29 | 11.29 | 14.23 | 17.83 |
| | b) Diluted | 4.23 | 2.83 | 6.29 | 11.29 | 14.23 | 17.83 |
| | | (not annualised) | (not annualised) | (not annualised) | (not annualised) | (not annualised) | (annualised) |

- Notes**
- 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 6th February, 2023. The above results have been subjected to limited review by the statutory auditors of the company.
 - 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
 - 3) The consolidated financial results include the results of the wholly owned subsidiaries Suven Pharma, Inc., USA & Casper Pharma Pvt Ltd, (wef from 22nd April '2022).
 - 4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
 - 5) The other Income (Standalone figures for the year-2021-22 includes an amount of Rs.15081.85 Lacs (Q2 Rs.3329.39 lacs & Q4 Rs.11752.46 lacs) pertaining to the Dividends received and Rs.1080.41 lacs (Q4) pertaining to Gain on Investments on part disinvestment of Capital from our Wholly Owned Subsidiary, Suven Pharma, Inc. The Current tax for the year 2021-22 (Standalone figures) includes an amount of Rs.1676.21 lacs (Q3 Rs.491.72 Lacs & Q4 Rs.1184.49 Lacs) withholding tax paid on such dividend by our wholly owned subsidiary.
 - 6) The Suven Pharma Inc., the WOS of our Company has divested its entire stake (25% amounting to \$35.00 Mn) in M/s Rising pharma Holdings, Inc., USA on 13th Dec, 2021 to Raisin Acquisition Co, Inc., one of the investment arms of H.I.G. Capital, USA through structured deal. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of US \$41.555 Mn and a stake valued at US \$15.803 Mn in Raisin Aggregators, L.P. Accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company w.e.f 13th Dec'2021
 - 7) Post approval of the Board in the meeting held on 5th April 2022, the company has completed acquisition of 100% stake in Casper Pharma Pvt Ltd, (SEZ company) engaged in formulations business for US \$20.50 Mn and has become a Wholly Owned Subsidiary of the Company w.e.f 22 nd April 2022. Subsequently subscribed the right issue in the ratio of 4:1 on 22/06/2022 of 52,16,156 shares of face value of Rs.10.00 with a premium of Rs.70.00 per share for Rs.4172.92 Lacs.
 - 8) The Promoter Group, Jasti Property and Equity Holdings Private Limited (in their capacity as sole trustee of Jasti Family Trust), informed the Company that they executed a Share Purchase Agreement to sell 12,75,37,043 Equity shares representing 50.10% of the Voting share capital to Berhyanda Limited company on 26th December 2022.
 - 9) The corresponding previous period figures have been regrouped/reclassified where ever necessary.

For SUVEN PHARMACEUTICALS LTD

Place : Hyderabad
Date : 6th February ' 2023

VENKAT JASTI
Managing Director
DIN: 00278028